Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational drugs for COVID-19 as new science emerges.
Epistemonikos ID: 337ae5f5df49dde01610559837f40a31e530277e
First added on: Apr 22, 2020